JP2024506099A5 - - Google Patents
Info
- Publication number
- JP2024506099A5 JP2024506099A5 JP2023548577A JP2023548577A JP2024506099A5 JP 2024506099 A5 JP2024506099 A5 JP 2024506099A5 JP 2023548577 A JP2023548577 A JP 2023548577A JP 2023548577 A JP2023548577 A JP 2023548577A JP 2024506099 A5 JP2024506099 A5 JP 2024506099A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- complex
- residue
- alkyl
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBPCT/GB2021/050357 | 2021-02-12 | ||
| PCT/GB2021/050357 WO2022171972A1 (en) | 2021-02-12 | 2021-02-12 | Cell-penetrating peptide conjugates and methods of their use |
| PCT/GB2022/050371 WO2022172019A1 (en) | 2021-02-12 | 2022-02-11 | Cell-penetrating peptide conjugates and methods of their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506099A JP2024506099A (ja) | 2024-02-08 |
| JP2024506099A5 true JP2024506099A5 (enExample) | 2025-02-17 |
Family
ID=74669201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548577A Pending JP2024506099A (ja) | 2021-02-12 | 2022-02-11 | 細胞透過性のペプチド複合体およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20240299563A1 (enExample) |
| EP (2) | EP4291244B1 (enExample) |
| JP (1) | JP2024506099A (enExample) |
| KR (1) | KR20240006019A (enExample) |
| CN (1) | CN117295525A (enExample) |
| AU (2) | AU2021427595A1 (enExample) |
| BR (1) | BR112023016183A2 (enExample) |
| CA (2) | CA3211038A1 (enExample) |
| ES (1) | ES3058927T3 (enExample) |
| IL (1) | IL305117A (enExample) |
| MX (1) | MX2023009446A (enExample) |
| WO (2) | WO2022171972A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200131231A1 (en) | 2017-02-17 | 2020-04-30 | Oxford University Innovation Limited | Cell penetrating peptides |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| US12465646B2 (en) | 2018-12-07 | 2025-11-11 | Oxford University Innovation Limited | Linkers |
| WO2022192749A2 (en) * | 2021-03-12 | 2022-09-15 | Pepgen Inc. | Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates |
| EP4304657A4 (en) * | 2021-03-12 | 2026-04-01 | Pepgen Inc | METHODS OF TREATMENT OF TYPE 1 MYOTONIC DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES |
| TW202442246A (zh) | 2023-04-27 | 2024-11-01 | 美商薩羅塔治療公司 | 用於治療慢性腎病之反義寡聚物 |
| WO2025085810A2 (en) | 2023-10-18 | 2025-04-24 | Sarepta Therapeutics, Inc. | Antisense oligomers for treatment of centronuclear myopathies |
| GB202405980D0 (en) * | 2024-04-29 | 2024-06-12 | Univ Oxford Innovation Ltd | Conjugate for treating repeat expansion disorders |
| WO2025264554A1 (en) | 2024-06-17 | 2025-12-26 | Pepgen Inc. | Antisense oligonucleotide conjugates targeting peripheral myelin protein 22 (pmp22) and methods of use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| EP2933332A1 (en) | 2004-06-28 | 2015-10-21 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| WO2009147368A1 (en) * | 2008-06-04 | 2009-12-10 | Medical Research Council | Peptides |
| BR122020021379B1 (pt) | 2008-10-24 | 2021-05-11 | Sarepta Therapeutics, Inc. | oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular |
| TR201816523T4 (tr) | 2009-11-12 | 2018-11-21 | Univ Western Australia | Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler. |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| CA3092114A1 (en) * | 2011-05-05 | 2012-11-08 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| US20140315977A1 (en) * | 2013-03-14 | 2014-10-23 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| PT3554552T (pt) * | 2016-12-19 | 2022-10-03 | Sarepta Therapeutics Inc | Conjugados de oligómero de skipping de exão para distrofia muscular |
| KR20240006023A (ko) * | 2016-12-19 | 2024-01-12 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| KR102810425B1 (ko) * | 2016-12-19 | 2025-05-21 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| US20200131231A1 (en) * | 2017-02-17 | 2020-04-30 | Oxford University Innovation Limited | Cell penetrating peptides |
| EP3687547A1 (en) * | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| WO2019067979A1 (en) * | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY |
| WO2019067981A1 (en) * | 2017-09-28 | 2019-04-04 | Sarepta Therapeutics, Inc. | POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY |
| US11555189B2 (en) * | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
| EP3765030A4 (en) * | 2018-03-16 | 2022-01-26 | Sarepta Therapeutics, Inc. | CHIMERIC PEPTIDES FOR ANTISENSE ADMINISTRATION |
| JP2021521794A (ja) * | 2018-04-26 | 2021-08-30 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
| JP7579147B2 (ja) * | 2018-06-14 | 2024-11-07 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
| TW202449155A (zh) * | 2018-07-27 | 2024-12-16 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812980D0 (en) * | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| US12465646B2 (en) | 2018-12-07 | 2025-11-11 | Oxford University Innovation Limited | Linkers |
| WO2020214763A1 (en) * | 2019-04-18 | 2020-10-22 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| JP2022536495A (ja) * | 2019-06-19 | 2022-08-17 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーを治療する方法 |
| GB201911403D0 (en) * | 2019-08-09 | 2019-09-25 | Univ Oxford Innovation Ltd | Conjugate and uses thereof |
-
2021
- 2021-02-12 WO PCT/GB2021/050357 patent/WO2022171972A1/en not_active Ceased
- 2021-02-12 CA CA3211038A patent/CA3211038A1/en active Pending
- 2021-02-12 AU AU2021427595A patent/AU2021427595A1/en active Pending
-
2022
- 2022-02-11 WO PCT/GB2022/050371 patent/WO2022172019A1/en not_active Ceased
- 2022-02-11 CN CN202280028220.8A patent/CN117295525A/zh active Pending
- 2022-02-11 IL IL305117A patent/IL305117A/en unknown
- 2022-02-11 EP EP22704422.9A patent/EP4291244B1/en active Active
- 2022-02-11 MX MX2023009446A patent/MX2023009446A/es unknown
- 2022-02-11 BR BR112023016183A patent/BR112023016183A2/pt unknown
- 2022-02-11 ES ES22704422T patent/ES3058927T3/es active Active
- 2022-02-11 JP JP2023548577A patent/JP2024506099A/ja active Pending
- 2022-02-11 EP EP25221967.0A patent/EP4717702A2/en active Pending
- 2022-02-11 AU AU2022220252A patent/AU2022220252A1/en active Pending
- 2022-02-11 US US18/277,013 patent/US20240299563A1/en active Pending
- 2022-02-11 CA CA3211042A patent/CA3211042A1/en active Pending
- 2022-02-11 KR KR1020237029218A patent/KR20240006019A/ko active Pending
-
2025
- 2025-02-14 US US19/054,315 patent/US20250177543A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506099A5 (enExample) | ||
| JP2024511955A5 (enExample) | ||
| CN103998458B (zh) | 具有中央疏水域的细胞穿透肽 | |
| JP7846169B2 (ja) | 細胞透過性ペプチド | |
| US8575305B2 (en) | Cell penetrating peptides | |
| CA3188410A1 (en) | Conjugated hepcidin mimetics | |
| JP7663492B2 (ja) | 細胞透過性ペプチド | |
| US12465646B2 (en) | Linkers | |
| JP7269968B2 (ja) | ペプチド担体上の多重オリゴヌクレオチド部分 | |
| US12583889B2 (en) | Cell penetrating peptides | |
| JP2021534131A5 (enExample) | ||
| JP2024511954A5 (enExample) | ||
| EP4353268A1 (en) | Nanoparticle comprising peptide-lipid conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same | |
| ES2683186T3 (es) | Monómeros y oligómeros de ácido peptidonucleico | |
| WO1995006056A1 (en) | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same | |
| Dastpeyman et al. | Modular synthesis of trifunctional peptide-oligonucleotide conjugates via native chemical ligation | |
| JP2021518361A5 (enExample) | ||
| RU2023123089A (ru) | Проникающие в клетки пептидные конъюгаты | |
| US20260021187A1 (en) | Linkers | |
| WO2024094980A1 (en) | Shortened cell-penetrating peptides | |
| RU2021105152A (ru) | Проникающие в клетку пептиды |